Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  25.00 0.64% 3,950.00 3,900.00 4,000.00 3,950.00 3,925.00 3,925.00 1,921 08:27:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.3 8.2 139.4 28.3 206

Bioventix Share Discussion Threads

Showing 1326 to 1349 of 1350 messages
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
DateSubjectAuthorDiscuss
30/7/2021
21:45
acutecaretesting.org/en/articles/troponin-testing-at-the-point-of-care-what-is-needed-and-when Worth reading for the tension between time and POC testing vs laboratory testing. apad
apad
29/7/2021
10:16
Yes, thanks. A closer look at the cash flow statement shows that is the case.
johnveals
29/7/2021
09:07
Interesting metrics. Steadily increasing revenue and profit, great ROCE and cash conversion, but this is not reflected in the balance sheet, where is this cash going?
johnveals
26/7/2021
15:22
Check out all the fractional trades at 1458h to push the price up artificially . This is to let Cannacord offload - don't fall for it by buying this rally. It is a fake.
doctor888
23/7/2021
16:30
I don't think it will make much progress until we see significant sales from Troponin.
stepone68
23/7/2021
14:09
If Cannaccord have stopped selling do we expect the share price to make progress? Suet
suetballs
21/7/2021
20:50
Now it makes sense - Canaccord sold their holding down from 10% to 5% - wonder if they will keep selling? SP has kept looking at the support level of 3800/3850 - dodgy fractional share trading to inflate the close price for the past week or so, hiding the large sales during the day. That's my interpretation anyway - any differences of opinion?
doctor888
19/7/2021
10:16
Does anyone know if Bioventix are involved with D Dimer tests? Or if not, which companies are? If this guy is right about about micro-clots in the capillaries, everyone who's had a vaccine is going to want a D-Dimer test hTTps://rumble.com/vjino9-dire-warning-from-dr.-charles-hoffe.html?fbclid=IwAR1rsu9vI6mWCPrZuxp5CdJwW8iQ6q80kQ7uSQWjxYJhUP0vLG-P7ZUlaac
edpick
16/7/2021
11:58
John Rosier mentions Bioventix (BVXP) in the latest PIWORLD interview at 12m14s Watch the video here: Https://www.piworld.co.uk/education-videos/piworld-interview-john-rosiers-portfolio-update-july-2021/ Or listen to the podcast here: Https://piworld.podbean.com/e/piworld-interview-john-rosiers-portfolio-update-july-2021/
tomps2
15/7/2021
09:40
that works fine Piedro. Worryingly, I am being treated for acute back pain by my Chiropractor - lord knows how old I'm becoming 'cos of all the inflamation :)
alter ego
15/7/2021
08:39
Sorry ae, that was an oversight. Try this one .... NEWS 13 July 2021 ‘Inflammation clock’ can reveal body’s biological age Using machine learning, researchers created a tool that might help doctors improve people’s healthy lifespan. ... evaluating a person’s biological age by measuring epigenetic changes to their DNA can be complicated. Measuring inflammation with a blood test would be easier ... hTTps://www.nature.com/articles/d41586-021-01915-x
piedro
15/7/2021
07:46
Interesting Piedro. By the way, you can prevent ADVFN corrupting the start of your link with xx in place of tt by using caps i.e. hTTps.
alter ego
14/7/2021
16:44
How’s my driving? GPS tracking spots Alzheimer’s with 86% accuracy Phil TaylorPhil TaylorJuly 13, 2021 Diagnosing Alzheimer’s disease is still a challenge, particularly in its earliest stages, but a new study suggests that subtle changes in behaviour whilst driving could serve as an early warning system. ... ... hTTps://pharmaphorum.com/news/hows-my-driving-gps-tracking-spots-alzheimers-with-86-accuracy/?utm_source=pharmaphorum+Daily+Newsletter&utm_campaign=5789a61024-EMAIL_CAMPAIGN_2019_09_24_10_10_COPY_01&utm_medium=email&utm_term=0_a54496134b-5789a61024-443779793
piedro
07/7/2021
08:50
Prima facie competitor. Now need to find an independent, refereed, academic paper. Siemens are promoting it hard. apad
apad
07/7/2021
08:47
"Dr. Fred Apple, PhD, Medical Director of clinical laboratories, clinical chemistry, point-of-care testing, and clinical and forensic toxicology laboratories at Hennepin County Medical Center. "The Siemens Healthineers Atellica VTLi point-of-care assay technology, utilizing whole blood with result turn-around times in as fast as eight minutes, provides a high-sensitivity cardiac troponin I measurement that is equivalent to the diagnostic and analytical accuracy of instruments found in the central laboratory. I believe this POC system could easily integrate into existing hospital and clinic workflows, with the potential to impact patient care and clinical outcomes, with operational and financial efficiencies.” The Atellica VTLi system has wireless capability that easily integrates and directly connects to data management systems, including the Siemens Healthineers POC Ecosystem Solution, and the laboratory and hospital information systems. Together, this offering provides the laboratory centralized control over decentralized point-of-care testing."
apad
07/7/2021
08:28
Https://doclib.siemens-healthineers.com/rest/v1/view?document-id=778535 The VTLi POC machine uses a mouse monoclonal antibody. I believe the VTLi machine was acquired from Phillips a couple years back which might explain why it doesn't use the Bioventix antibody.
gsbmba99
06/7/2021
09:24
Gorrit - cut the laboratory out of the loop. apad "Point-of-Care Cardiac Troponin Testing Central laboratories are not always on-site, nor available for use 24 hours a day, seven days a week. Point-of-care (POC) testing is a care model that moves the assay to the patient and is now available to measure cTn levels. POC cTn tests offer a significantly shorter turnaround time for biomarker detection, typically providing results within 10 to 20 minutes.4 POC cTn testing has been used with the goal to expedite patient care both in hospital emergency departments and in various settings where central laboratory testing is not available, including use by paramedics aboard a land or air ambulance, and by health personnel in rural health care centres or remote locations. Use of POC cTn testing could potentially speed up therapeutic decisions and decisions around patient transfers, hospital admissions, and discharge for patients presenting with ACS. Theoretically, the result could be less congested emergency departments and fewer transfers of patients to larger hospitals for further assessment. Improved patient flow may result in cost reductions from fewer unnecessary hospital admissions and laboratory costs.9 POC cTn testing is more expensive than laboratory testing, with one manufacturer citing $12.50 per test. However, a cost-per-test approach is not an informative cost comparison with laboratory testing; rather, the question is how POC testing compares with laboratory testing when examining factors beyond the costs of reagents to include the costs of running the POC program (for example, training, quality assurance and quality control, maintenance, data management) and savings from avoiding the costs of patient transfers and hospital admissions. There are several POC troponin devices available in Canada produced by various manufacturers that test for one or both types of cTn (cTnI and cTnT). A list of POC troponin devices approved in Canada is provided in Appendix 1. Go to: 1.4. Decision-Making About Point-of-Care Troponin Testing It is unknown whether health outcomes can be improved and if cost savings can be realized with POC cTn testing in various Canadian health care settings (such as hospitals with a central laboratory, community hospitals, remote locations, hospitals without a central laboratory, remote nursing stations, medical clinics, long-term care settings, and emergency medical services). To answer these questions, a review of the clinical and economic evidence on POC troponin testing is needed to inform decisions about its acquisition and use."
apad
06/7/2021
09:20
"Good spot. Unless it is much more specific than current assays, not sure about the clinical need for another troponin assay." Particularly as BVXP's is approved and the cost/time for a new approval is very high. There must be something that we don't know. Haven't been able to find anything else. SP stagnation is unsurprising. News in Oct. and they don't do intermediate rns. apad
apad
06/7/2021
09:10
Good spot. Unless it is much more specific than current assays, not sure about the clinical need for another troponin assay. Any thoughts on the share price drop of late? Just got the death cross (20d under 50d MA). I thought that NICE recommending Vitamin D for all would reduce assay measurement, which the company has forecast. However, Vitamin D revenues have continued to grow to date.
doctor888
01/7/2021
08:18
Long article behind paywall Siemens Healthineers Rolling Out High-Sensitivity POC Troponin Assay in Europe "...Siemens Healthineers recently began shipping its first Atellica VTLi Patient-Side Immunoassay Analyzers with a test for troponin I, a protein biomarker of acute myocardial infarction, to hospital emergency departments in Europe." "...By establishing a footprint in Europe and other regions that accept CE marking, the firm gains an early-mover advantage in the testing market for cardiac conditions at the point of care" and "...the first p-o-c high-sensitivity cardiac troponin I test with results comparable to laboratory performance using just a fingerstick sample" Christoph Pedain, head of point-of-care diagnostics at Siemens Healthineers said Also conducting a clinical validation study to prepare for a submission for FDA clearance though timeline for the submission is uncertain. hTTps://www.360dx.com/business-news/siemens-healthineers-rolling-out-high-sensitivity-poc-troponin-assay-europe#.YN1pSuhKhPY
pob69
06/5/2021
20:32
I suspect its unlikely as the 3 monoclonal antibodies on the UK market (Erenumab, Fremanezumab and Galcanezumab) and the one that is under review by NICE (Eptinezumab) are all humanized monoclonals rather than sheep monoclonals.
ppio
05/5/2021
09:07
Just read an interesting article on King’s College London’s work on a possible cure for migraine using monoclonal antibodies. No mention of who supplies the antibodies but may have to ask BVXP if they are involved. Apparently one billion people around the World suffer from migraines so this could be huge for whoever manufactures the antibodies. hxxps://www.kcl.ac.uk/news/professor-peter-goadsby-awarded-worlds-top-brain-prize-2021
scillyfool
04/5/2021
08:56
Blog posting profiling BVXP hTTps://www.musingmarkets.com/post/april-2021-u-k-stock-pick
pob69
23/4/2021
18:49
Still nothing via my AJ Bell account. The same thing happened with ABDP a few weeks ago when I got mine two working days after everyone with holdings elsewhere. Not impressed.
jurgenklopp
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
ADVFN Advertorial
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 18:27:30